logologologologo
  • Home
  • Business
  • Markets
  • Exchange
  • Investment
  • Personal Finance

Teladoc Stock: Buy, Sell or Hold In 2022?

As we begin 2022, many companies are still being impacted by the effects of the pandemic. At the top of that list is Teladoc Health, the telehealth company that saw its usage and stock price surge during the height of the pandemic as patients needing medical care turned to its platform to see doctors virtually.

Considering this backdrop, investors could expect to see Teladoc’s results tapering off, fitting the company neatly into the pandemic stock narrative. However, the actual results over the past few quarters tell a different story. So should investors buy, sell, or hold Teladoc in 2022? Let’s take a look.

Continued strong growth

In the third quarter of 2021, Teladoc reported year-over-year revenue growth of 81%,  continuing a streak of sequential revenue growth since the beginning of 2019. On its own, the 81% revenue growth is excellent, but it’s even more impressive considering that Q3 of 2020 featured growth of 108%. It’s much easier to see a doctor now than it was in Q3 of 2020, so this growth suggests that Teladoc is an attractive option for patients even when in-person visits are a more viable option. While it’s true that this 81% growth was a deceleration from the triple-digit growth seen in the previous four quarters, it’s important to remember that in Q4 of 2019, revenue growth was only 24%. Although the pandemic may have pulled forward some growth, it’s clear patients are sticking with the platform.

What’s driving this revenue growth? In Q3, there were more than 3.9 million visits to the Teladoc platform, a 37% increase over Q3 of 2020, and an 11% increase sequentially. These telehealth visits bring in access fees, which are the majority of the company’s revenues. Access fee revenue in Q3 increased 99% year over year, with U.S. access fees increasing 113%. These were both off of tough comps of 90% and 111% year-over-year growth in Q3 of 2020.

There’s an important detail within the access fee data as well. Access fee revenue now comprises 87% of total revenue, up from 78% in the third quarter of 2020. This is higher-margin subscription revenue and helps explain why Teladoc’s gross margins have improved over the past year. Additionally, management attributed the growth in access fee revenue as a percentage of total revenue to its Livongo acquisition, showing the benefits of that merger coming to fruition.

A move toward holistic telehealth

Teladoc is also seeing its clients stay with the platform and add more services over time. In the Q3 earnings call, management stated that repeat usage was up 25% year over year, and 70% of the year’s bookings were multi-product sales, compared to 50% in the year prior. This plays into Teladoc’s Primary360 product, which the company calls “a fully integrated solution of mental and physical health.” During Q3, Teladoc signed agreements with CVS and Centene to expand this offering.

A gift from the market

The stock has taken a beating over the past year, in stark contrast to the business’s results. Shares now sell for the same price as they did at the beginning of 2020. Turning to valuation, Teladoc is trading for only five times its forward sales, the lowest this multiple has been in two years. Telehealth is here to stay and is predicted to grow from its 2020 market size of $144 billion to $637 billion by 2028.

Considering its position as the preeminent name in this important and growing market, as well as its current valuation, Teladoc looks like a buy in 2022. Also, investors who already own shares could view the stock’s sell-off as an opportune time to add to their position. For those who may still be on the fence, there’s still time to watch the next few quarters’ results before making a decision. Teladoc has room to grow and it should reward shareholders for decades to come.

Related posts

February 7, 2023

Google launches ChatGPT competitor in strike at Microsoft


Read more

Categories

  • Business
  • Content
  • Exchange
  • Inflation
  • Investment
  • Markets
  • Personal Finance
  • Technology
  • Uncategorized

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021

Recent Posts

  • Google launches ChatGPT competitor in strike at Microsoft
  • Factbox-U.S. stock buybacks so far in 2023: big money, fewer companies
  • Spotify upgraded at Wells Fargo as company comes off ‘margin probation’
  • Rally in focus, Powell speaks, more earnings pour in: What to know this week
  • Where Will AMD Stock Be In 1 Year?

About Us

The Alpha Cut a Vida Street LLC Company
1404 N. Ronald Reagan Blvd.
Suite 1120
Longwood, FL 32750

Link

(843) 256-4375
https://thealphacut.com

Why Us

Terms & Privacy
Policy & Procedure
Disclaimer

This material is not an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only.
Any performance results discussed herein represent past performance, not a guarantee of future performance, and are not indicative of any specific investment. Due to the timing of information presented, investment performance may be adjusted after the publication of this report. There can be no assurance that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this communication will be profitable, equal any corresponding indicated historical performance levels or be suitable for your portfolio.
All data in this communication is provided for informational purposes only and is not intended for trading or investing purposes. We expressly disclaim the accuracy, adequacy, or completeness of any data and content provided by financial exchanges, individual issuers, their respective affiliates and business partners and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining our prior written consent.
We make no express or implied warranties or representations and shall have no liability whatsoever with respect to any data contained herein. The data may not be further redistributed or used to create indices or other financial products. This report and the views expressed herein are subject to change at any time based upon market or other conditions (such as domestic and global economic trends) and are current as of the date of publication hereof. The information, analysis, and opinions expressed herein are for general information only and are not intended to provide specific advice or recommendations for any individual or entity.
We emphasize that Investment in the securities of smaller companies can involve greater risk than is generally associated with investment in larger, more established companies, and can result in significant capital losses that may have a detrimental effect on the value of your investments.
Forecasting represents predictions of market prices and/or volume patterns utilizing varying analytical data. It is not representative of a projection of the stock market, or of any specific investment.
Nothing contained in this material is intended to constitute legal, tax, securities or investment advice, nor an opinion regarding the appropriateness of any investment. The general information contained in this publication should not be acted upon without obtaining specific legal, tax and investment advice from a licensed professional.
Please remember that all investments carry some level of risk, including the potential loss of principal invested. They do not typically grow at an even rate of return and may experience negative growth.As with any structuring of a portfolio of investments, attempting to reduce risk and increase return could, at certain times, unintentionally reduce returns.
The information, analysis and opinions expressed herein are for general, impersonal information only and are not intended to provide specific advice or recommendations for any individual entity.

copyright © Alpha Cut 2021. All Right Reserved
The Alpha Cut a Vida Street LLC Company